These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
67 related articles for article (PubMed ID: 26240993)
1. Increased incidence of intermittent hypoxemia in the Ts65Dn mouse model of Down syndrome. Das D; Medina B; Baktir MA; Mojabi FS; Fahimi A; Ponnusamy R; Salehi A Neurosci Lett; 2015 Sep; 604():91-6. PubMed ID: 26240993 [TBL] [Abstract][Full Text] [Related]
2. Abnormal expression of the G-protein-activated inwardly rectifying potassium channel 2 (GIRK2) in hippocampus, frontal cortex, and substantia nigra of Ts65Dn mouse: a model of Down syndrome. Harashima C; Jacobowitz DM; Witta J; Borke RC; Best TK; Siarey RJ; Galdzicki Z J Comp Neurol; 2006 Feb; 494(5):815-33. PubMed ID: 16374808 [TBL] [Abstract][Full Text] [Related]
3. Formoterol, a long-acting β2 adrenergic agonist, improves cognitive function and promotes dendritic complexity in a mouse model of Down syndrome. Dang V; Medina B; Das D; Moghadam S; Martin KJ; Lin B; Naik P; Patel D; Nosheny R; Wesson Ashford J; Salehi A Biol Psychiatry; 2014 Feb; 75(3):179-88. PubMed ID: 23827853 [TBL] [Abstract][Full Text] [Related]
4. Three-dimensional synaptic ultrastructure in the dentate gyrus and hippocampal area CA3 in the Ts65Dn mouse model of Down syndrome. Popov VI; Kleschevnikov AM; Klimenko OA; Stewart MG; Belichenko PV J Comp Neurol; 2011 May; 519(7):1338-54. PubMed ID: 21452200 [TBL] [Abstract][Full Text] [Related]
5. Functional and biochemical characterization of soleus muscle in Down syndrome mice: insight into the muscle dysfunction seen in the human condition. Cowley PM; Keslacy S; Middleton FA; DeRuisseau LR; Fernhall B; Kanaley JA; DeRuisseau KC Am J Physiol Regul Integr Comp Physiol; 2012 Dec; 303(12):R1251-60. PubMed ID: 23115123 [TBL] [Abstract][Full Text] [Related]
6. Deficits of neuronal density in CA1 and synaptic density in the dentate gyrus, CA3 and CA1, in a mouse model of Down syndrome. Kurt MA; Kafa MI; Dierssen M; Davies DC Brain Res; 2004 Oct; 1022(1-2):101-9. PubMed ID: 15353219 [TBL] [Abstract][Full Text] [Related]
7. Breathing and Oxygen Carrying Capacity in Ts65Dn and Down Syndrome. DeRuisseau LR; Receno CN; Cunningham C; Bates ML; Goodell M; Liang C; Eassa B; Pascolla J; DeRuisseau KC Function (Oxf); 2023; 4(6):zqad058. PubMed ID: 37954975 [TBL] [Abstract][Full Text] [Related]
8. Synaptic and cognitive abnormalities in mouse models of Down syndrome: exploring genotype-phenotype relationships. Belichenko PV; Kleschevnikov AM; Salehi A; Epstein CJ; Mobley WC J Comp Neurol; 2007 Oct; 504(4):329-45. PubMed ID: 17663443 [TBL] [Abstract][Full Text] [Related]
9. Normalization of Dyrk1A expression by AAV2/1-shDyrk1A attenuates hippocampal-dependent defects in the Ts65Dn mouse model of Down syndrome. Altafaj X; Martín ED; Ortiz-Abalia J; Valderrama A; Lao-Peregrín C; Dierssen M; Fillat C Neurobiol Dis; 2013 Apr; 52():117-27. PubMed ID: 23220201 [TBL] [Abstract][Full Text] [Related]
10. Hippocampal hypocellularity in the Ts65Dn mouse originates early in development. Lorenzi HA; Reeves RH Brain Res; 2006 Aug; 1104(1):153-9. PubMed ID: 16828061 [TBL] [Abstract][Full Text] [Related]
11. Behavioral and neurobiological markers of Alzheimer's disease in Ts65Dn mice: effects of estrogen. Hunter CL; Bimonte-Nelson HA; Nelson M; Eckman CB; Granholm AC Neurobiol Aging; 2004 Aug; 25(7):873-84. PubMed ID: 15212841 [TBL] [Abstract][Full Text] [Related]
12. Nest building is impaired in the Ts65Dn mouse model of Down syndrome and rescued by blocking 5HT2a receptors. Heller HC; Salehi A; Chuluun B; Das D; Lin B; Moghadam S; Garner CC; Colas D Neurobiol Learn Mem; 2014 Dec; 116():162-71. PubMed ID: 25463650 [TBL] [Abstract][Full Text] [Related]
13. Impaired plasticity at specific subset of striatal synapses in the Ts65Dn mouse model of Down syndrome. Di Filippo M; Tozzi A; Ghiglieri V; Picconi B; Costa C; Cipriani S; Tantucci M; Belcastro V; Calabresi P Biol Psychiatry; 2010 Apr; 67(7):666-71. PubMed ID: 19818432 [TBL] [Abstract][Full Text] [Related]
14. Long-term running alleviates some behavioral and molecular abnormalities in Down syndrome mouse model Ts65Dn. Kida E; Rabe A; Walus M; Albertini G; Golabek AA Exp Neurol; 2013 Feb; 240():178-89. PubMed ID: 23201095 [TBL] [Abstract][Full Text] [Related]
15. Synaptic structural abnormalities in the Ts65Dn mouse model of Down Syndrome. Belichenko PV; Masliah E; Kleschevnikov AM; Villar AJ; Epstein CJ; Salehi A; Mobley WC J Comp Neurol; 2004 Dec; 480(3):281-98. PubMed ID: 15515178 [TBL] [Abstract][Full Text] [Related]
16. Speeding of miniature excitatory post-synaptic currents in Ts65Dn cultured hippocampal neurons. Best TK; Cho-Clark M; Siarey RJ; Galdzicki Z Neurosci Lett; 2008 Jun; 438(3):356-61. PubMed ID: 18490108 [TBL] [Abstract][Full Text] [Related]
17. Age-related changes in memory and in acetylcholine functions in the hippocampus in the Ts65Dn mouse, a model of Down syndrome. Chang Q; Gold PE Neurobiol Learn Mem; 2008 Feb; 89(2):167-77. PubMed ID: 17644430 [TBL] [Abstract][Full Text] [Related]
18. α-Tocopherol suppresses lipid peroxidation and behavioral and cognitive impairments in the Ts65Dn mouse model of Down syndrome. Shichiri M; Yoshida Y; Ishida N; Hagihara Y; Iwahashi H; Tamai H; Niki E Free Radic Biol Med; 2011 Jun; 50(12):1801-11. PubMed ID: 21447382 [TBL] [Abstract][Full Text] [Related]
19. Ultrasonic vocalizations during male-female interaction in the mouse model of Down syndrome Ts65Dn. Zampieri BL; Fernandez F; Pearson JN; Stasko MR; Costa AC Physiol Behav; 2014 Apr; 128():119-25. PubMed ID: 24534182 [TBL] [Abstract][Full Text] [Related]
20. Long-term effects of neonatal treatment with fluoxetine on cognitive performance in Ts65Dn mice. Stagni F; Giacomini A; Guidi S; Ciani E; Ragazzi E; Filonzi M; De Iasio R; Rimondini R; Bartesaghi R Neurobiol Dis; 2015 Feb; 74():204-18. PubMed ID: 25497735 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]